COST-EFFECTIVENESS COMPARISON OF GENOTYPE 1 HEPATITIS C VIRUS (HCV) TREATMENTS USING TELAPREVIR (TVR) IN PATIENTS WITH MILD FIBROSIS VS. PATIENTS WITH BRIDGING FIBROSIS AND CIRRHOSIS
Author(s)
D'Angelo ER*1;Gonzalez E2, Sola R2 1Janssen-Cilag SA, MADRID, MADRID, Spain, 2Hospital del Mar, BARCELONA, Spain
OBJECTIVES: To estimate, from a Spanish Healthcare System perspective, the cost-effectiveness of the usage of telaprevir (TVR) with peginterferon and ribavirin (PR) in patients with mild fibrosis (METAVIR F2) vs. patients with bridging fibrosis or cirrhosis (METAVIR scores F3 and F4, respectively). METHODS: A decision tree model was developed to assess cost-efficacy of TVR+PR according to the degree of fibrosis and previous response to treatment in patients with HCV Genotype 1. Treatment costs were estimated excluding futility rules but contemplating the potential to shorten treatment in treatment-naïve and relapsers that are either F2 or F3. The efficacy of triple therapy treatment by patient type is derived from the TVR phase III clinical trials. To estimate cost-effectiveness, the following values were calculated for each alternative: the cost per cured patient and the number of cured and not cured patients assuming a fixed budget. RESULTS: TVR+PR in F2 patients has a lower cost per cured patient than F3+F4 both in naïve patients (20% less) and in experienced patients (in relapsers: 5% less; in partial responders: 47% less; and in null responders: 39% less). This difference is statistically significant for naïve and partial responding patients. For a 1 million EUR investment in each patient type, resources allocated to F2 patients offers maximum cured patients (94 in F2 vs. 71 in F3+F4) and minimum non-cured patients (37 in F2 vs. 58 in F3+F4). This conclusion stands when different sensitivity analyses are conducted. CONCLUSIONS: The usage of TVR+PR in patients with mild fibrosis could be a more cost-effective alternative than in patients with bridging fibrosis or cirrhosis regardless of the patient’s previous response to treatment. A long-term cost-effectiveness analysis is required in order to validate this data.
Conference/Value in Health Info
2013-11, ISPOR Europe 2013, The Convention Centre Dublin
Value in Health, Vol. 16, No. 7 (November 2013)
Code
PIN79
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine), Multiple Diseases